1444PA randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). (23rd October 2018) - Stinchcombe, T E; Janne, P A; Wang, X; Bertino, E M; Weiss, J M; Bazhenova, L; Gu, L; Lau, C J; Paweletz, C P; Jaslowski, A J; Gerstner, G J; Baggstrom, M Q; et al.